|
1
|
Liu Y, O'Leary CE, Wang LS, Bhatti TR, Dai
N, Kapoor V, Liu P, Mei J, Guo L, Oliver PM, et al: CD11b+Ly6G+
cells inhibit tumor growth by suppressing IL-17 production at early
stages of tumorigenesis. OncoImmunology. 5:e10611752015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ostrand-Rosenberg S and Sinha P:
Myeloid-derived suppressor cells: Linking inflammation and cancer.
J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mougiakakos D, Choudhury A, Lladser A,
Kiessling R and Johansson CC: Regulatory T cells in cancer. Adv
Cancer Res. 107:57–117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fichtner-Feigl S, Terabe M, Kitani A,
Young CA, Fuss I, Geissler EK, Schlitt HJ, Berzofsky JA and Strober
W: Restoration of tumor immunosurveillance via targeting of
interleukin-13 receptor-alpha 2. Cancer Res. 68:3467–3475. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagaraj S, Schrum AG, Cho H-I, Celis E and
Gabrilovich DI: Mechanism of T cell tolerance induced by
myeloid-derived suppressor cells. J Immunol. 184:3106–3116. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alhamarneh O, Agada F, Madden L, Stafford
N and Greenman J: Serum IL10 and circulating CD4(+) CD25(high)
regulatory T cell numbers as predictors of clinical outcome and
survival in patients with head and neck squamous cell carcinoma.
Head Neck. 33:415–423. 2011.PubMed/NCBI
|
|
7
|
Shevach EM: Regulatory T cells in
autoimmmunity. Annu Rev Immunol. 18:423–449. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen S, Akbar SMF, Abe M, Hiasa Y and Onji
M: Immuno-suppressive functions of hepatic myeloid-derived
suppressor cells of normal mice and in a murine model of chronic
hepatitis B virus. Clin Exp Immunol. 166:134–142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu
W, Shen C, Liu J and Ren X: Myeloid-derived suppressor cells
suppress antitumor immune responses through IDO expression and
correlate with lymph node metastasis in patients with breast
cancer. J Immunol. 190:3783–3797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsiganov EN, Verbina EM, Radaeva TV,
Sosunov VV, Kosmiadi GA, Nikitina IY and Lyadova IV: Gr-1dimCD11b+
immature myeloid-derived suppressor cells but not neutrophils are
markers of lethal tuberculosis infection in mice. J Immunol.
192:4718–4727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Youn J-I, Nagaraj S, Collazo M and
Gabrilovich DI: Subsets of myeloid-derived suppressor cells in
tumor-bearing mice. J Immunol. 181:5791–5802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rutkowski MR, Stephen TL, Svoronos N,
Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Brencicova E,
Escovar-Fadul X, Nguyen JM, Cadungog MG, et al: Microbially driven
TLR5-dependent signaling governs distal malignant progression
through tumor-promoting inflammation. Cancer Cell. 27:27–40. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang JC, Kundra A, Andrei M, Baptiste S,
Chen C, Wong C and Sindhu H: Myeloid-derived suppressor cells in
patients with myeloproliferative neoplasm. Leuk Res. 43:39–43.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stiff A, Trikha P, Wesolowski R, Kendra K,
Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, et
al: Myeloid-derived suppressor cells express Bruton's tyrosine
kinase and can be depleted in tumor-bearing hosts by ibrutinib
treatment. Cancer Res. 76:2125–2136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Highfill SL, Rodriguez PC, Zhou Q, Goetz
CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody
JS, Munn DH, et al: Bone marrow myeloid-derived suppressor cells
(MDSCs) inhibit graft-versus-host disease (GVHD) via an
arginase-1-dependent mechanism that is up-regulated by
interleukin-13. Blood. 116:5738–5747. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pesu M, Watford WT, Wei L, Xu L, Fuss I,
Strober W, Andersson J, Shevach EM, Quezado M, Bouladoux N, et al:
T-cell-expressed proprotein convertase furin is essential for
maintenance of peripheral immune tolerance. Nature. 455:246–250.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu L, Kitani A, Stuelten C, McGrady G,
Fuss I and Strober W: Positive and negative transcriptional
regulation of the Foxp3 gene is mediated by access and binding of
the Smad3 protein to enhancer I. Immunity. 33:313–325. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alhamarneh O, Amarnath SMP, Stafford ND
and Greenman J: Regulatory T cells: What role do they play in
antitumor immunity in patients with head and neck cancer? Head
Neck. 30:251–261. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Zhang P, Li J, Kulkarni AB,
Perruche S and Chen W: A critical function for TGF-beta signaling
in the development of natural CD4+CD25+Foxp3+ regulatory T cells.
Nat Immunol. 9:632–640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gabitass RF, Annels NE, Stocken DD, Pandha
HA and Middleton GW: Elevated myeloid-derived suppressor cells in
pancreatic, esophageal and gastric cancer are an independent
prognostic factor and are associated with significant elevation of
the Th2 cytokine interleukin-13. Cancer Immunol Immunother.
60:1419–1430. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamazaki T, Masuda J, Omori T, Usui R,
Akiyama H and Maru Y: EphA1 interacts with integrin-linked kinase
and regulates cell morphology and motility. J Cell Sci.
122:243–255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takayama E, Seki S, Ohkawa T, Ami K, Habu
Y, Yamaguchi T, Tadakuma T and Hiraide H: Mouse CD8+ CD122+ T cells
with intermediate TCR increasing with age provide a source of early
IFN-gamma production. J Immunol. 164:5652–5658. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terabe M, Matsui S, Park J-M, Mamura M,
Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt
B, et al: Transforming growth factor-beta production and myeloid
cells are an effector mechanism through which CD1d-restricted T
cells block cytotoxic T lymphocyte-mediated tumor
immunosurveillance: Abrogation prevents tumor recurrence. J Exp
Med. 198:1741–1752. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Holmgaard RB, Zamarin D, Li Y, Gasmi B,
Munn DH, Allison JP, Merghoub T and Wolchok JD: Tumor-expressed IDO
recruits and activates MDSCs in a Treg-dependent manner. Cell Rep.
13:412–424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yao Y, Vent-Schmidt J, McGeough MD, Wong
M, Hoffman HM, Steiner TS and Levings MK: Tr1 cells, but not Foxp3+
regulatory T cells, suppress NLRP3 inflammasome activation via an
IL-10-dependent mechanism. J Immunol. 195:488–497. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Redford PS, Murray PJ and O'Garra A: The
role of IL-10 in immune regulation during M. tuberculosis
infection. Mucosal Immunol. 4:261–270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saraiva M and O'Garra A: The regulation of
IL-10 production by immune cells. Nat Rev Immunol. 10:170–181.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beriou G, Bradshaw EM, Lozano E,
Costantino CM, Hastings WD, Orban T, Elyaman W, Khoury SJ, Kuchroo
VK, Baecher-Allan C, et al: TGF-beta induces IL-9 production from
human Th17 cells. J Immunol. 185:46–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao Y, Wu T, Shao S, Shi B and Zhao Y:
Phenotype, development, and biological function of myeloid-derived
suppressor cells. OncoImmunology. 5:e10049832015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Heerboth S, Housman G, Leary M, Longacre
M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor
metastasis. Clin Transl Med. 4:62015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Wang Z, Mao K and Guo X: Clinical
significance of serum T helper 1/T helper 2 cytokine shift in
patients with non-small cell lung cancer. Oncol Lett. 8:1682–1686.
2014.PubMed/NCBI
|
|
33
|
Hong C-C, Yao S, McCann SE, Dolnick RY,
Wallace PK, Gong Z, Quan L, Lee KP, Evans SS, Repasky EA, et al:
Pretreatment levels of circulating Th1 and Th2 cytokines, and their
ratios, are associated with ER-negative and triple negative breast
cancers. Breast Cancer Res Treat. 139:477–488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liang J, Li Y, Liu X, Xu X and Zhao Y:
Relationship between cytokine levels and clinical classification of
gastric cancer. Asian Pac J Cancer Prev. 12:1803–1806.
2011.PubMed/NCBI
|
|
35
|
Seledtsov VI, Goncharov AG and Seledtsova
GV: Clinically feasible approaches to potentiating cancer
cell-based immunotherapies. Hum Vaccin Immunother. 11:851–869.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sato M, Goto S, Kaneko R, Ito M, Sato S
and Takeuchi S: Impaired production of Th1 cytokines and increased
frequency of Th2 subsets in PBMC from advanced cancer patients.
Anticancer Res. 18D:3951–3955. 1998.
|
|
37
|
Szaflarska A, Szczepanik A, Siedlar M,
Czupryna A, Sierzega M, Popiela T and Zembala M: Preoperative
plasma level of IL-10 but not of proinflammatory cytokines is an
independent prognostic factor in patients with gastric cancer.
Anticancer Res. 29:5005–5012. 2009.PubMed/NCBI
|
|
38
|
Kozłowski L, Zakrzewska I, Tokajuk P and
Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6),
interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of
breast cancer patients. Rocz Akad Med Bialymst. 48:82–84.
2003.PubMed/NCBI
|
|
39
|
Asadullah K, Sterry W and Volk HD:
Interleukin-10 therapy - review of a new approach. Pharmacol Rev.
55:241–269. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Habu Y, Seki S, Takayama E, Ohkawa T,
Koike Y, Ami K, Majima T and Hiraide H: The mechanism of a
defective IFN-γ response to bacterial toxins in an atopic
dermatitis model, NC/Nga mice, and the therapeutic effect of IFN-γ,
IL-12, or IL-18 on dermatitis. J Immunol. 166:5439–5447. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Noelle RJ and Nowak EC: Cellular sources
and immune functions of interleukin-9. Nat Rev Immunol. 10:683–687.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu Y, Hong S, Li H, Park J, Hong B, Wang
L, Zheng Y, Liu Z, Xu J, He J, et al: Th9 cells promote antitumor
immune responses in vivo. J Clin Invest. 122:4160–4171. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang Y, Cao Y, Zhang S and Gao F:
Association between low expression levels of interleukin-9 and
colon cancer progression. Exp Ther Med. 10:942–946. 2015.PubMed/NCBI
|
